| UniProt |
Q9BYU8 |
| Gene |
ATP13A2 |
| Protein Size |
3,978 amino acids |
| Molecular Weight |
~446 kDa |
| ATPase Type |
P5B-type (P-type ATPase family) |
| Subcellular Location |
Lysosomal membrane, Late endosomes |
| Transmembrane Domains |
10 |
| Tissue Expression |
Brain (substantia nigra, basal ganglia), Liver, Kidney |
| Associated Diseases |
Parkinson's Disease, Kufor-Rakeb Syndrome, Neuronal Ceroid Lipofuscinosis |
ATP13A2 (also known as PARK9) is a member of the P-type ATPase family of cation transporters. As a P5B-type ATPase, this protein utilizes ATP hydrolysis to transport cationic substrates across biological membranes, primarily localizing to lysosomal and late endosomal membranes throughout the body. The protein plays a critical role in maintaining metal cation homeostasis within the lysosomal lumen, particularly for manganese (Mn²⁺), zinc (Zn²⁺), and potentially iron (Fe²⁺/Fe³⁺).
The ATP13A2 protein is encoded by the ATP13A2 gene, located on chromosome 1p36.13. With a molecular weight of approximately 446 kDa and containing 3,978 amino acids, ATP13A2 is one of the largest known P-type ATPases. The protein is composed of 10 transmembrane domains that form a channel for cation passage, along with conserved cytoplasmic domains responsible for ATP binding and phosphorylation.
Mutations in ATP13A2 cause Kufor-Rakeb syndrome (KRS), a rare autosomal recessive form of parkinsonism characterized by early-onset Parkinsonism, supranuclear gaze palsy, and pyramidal signs. More recent research has implicated ATP13A2 dysfunction in the broader pathogenesis of sporadic Parkinson's disease, where the protein plays essential roles in lysosomal function, autophagy, and neuronal survival.
¶ Domain Architecture
ATP13A2 exhibits the canonical domain structure of P-type ATPases, adapted for its role as a lysosomal cation transporter:
Transmembrane Domain:
- 10 transmembrane helices (M1-M10) that span the lysosomal membrane
- Form a channel allowing passage of cationic substrates
- The cation-binding site is located within the transmembrane region
- Conserved residues in the channel determine ion specificity
Cytoplasmic Domains:
- Actuator domain (A-domain): Contains the conserved DKTGTLT motif with an essential aspartate residue that undergoes phosphorylation during the catalytic cycle
- Phosphorylation domain (P-domain): Binds ATP and contains the phosphorylation site
- Nucleotide-binding domain (N-domain): Catalyzes ATP hydrolysis and couples energy to conformational changes
Cryo-electron microscopy studies have revealed several key structural features:
-
E1-E2 conformational cycle: The protein alternates between E1 (cytoplasm-facing, high-affinity) and E2 (lumen-facing, low-affinity) conformations during the transport cycle
-
Ion binding pocket: Conserved acidic residues (aspartate and glutamate) coordinate cation binding with preferences for manganese over other divalent cations
-
Regulatory domains: The A-domain acts as a hinge that transmits conformational changes from the P-domain to the transmembrane channel
-
Lysosomal targeting: A C-terminal di-acidic motif (D/E)X(D/E) mediates exit from the endoplasmic reticulum and trafficking to lysosomes
The primary physiological function of ATP13A2 is the ATP-dependent transport of cationic substrates across the lysosomal membrane:
Manganese Transport:
- Highest affinity substrate with Km values in the 10-20 μM range
- Essential for lysosomal manganese sequestration, preventing cytoplasmic accumulation
- Critical for neuronal health given manganese's neurotoxicity at elevated concentrations
Zinc Transport:
- Lower affinity (Km ~ 50-100 μM) but physiologically significant
- Modulates synaptic zinc signaling
- Important for lysosomal zinc homeostasis
Iron Transport:
- Variable affinity depending on oxidation state
- May contribute to preventing iron-mediated oxidative damage
- The exact substrate profile remains under investigation
The P-type ATPase catalytic cycle involves several key steps:
- E1 state: Protein binds cation from the cytoplasm with high affinity
- ATP binding: ATP binds to the N-domain
- Phosphorylation: The γ-phosphate of ATP is transferred to an aspartate residue in the A-domain (DKTGTLT motif)
- Conformational change: Phosphorylation triggers a conformational shift to the E2 state, reducing cation affinity
- Cation release: Cation is released into the lysosomal lumen
- Dephosphorylation: The phosphate is hydrolyzed, returning the protein to the E1 state
This vectorial transport mechanism allows cells to concentrate cations within lysosomes against their electrochemical gradient.
Beyond cation transport, ATP13A2 supports overall lysosomal function:
- pH maintenance: Cation transport contributes to lysosomal electrochemical balance
- Enzyme activation: Proper lysosomal pH (~4.5-5.0) is required for cathepsin activity
- Membrane potential: ATP13A2 activity influences the lysosomal membrane potential
¶ Expression and Localization
ATP13A2 protein shows highest expression in:
Central Nervous System:
- Substantia nigra pars compacta (dopaminergic neurons)
- Basal ganglia (caudate nucleus, putamen, globus pallidus)
- Cerebral cortex (particularly layer 5 pyramidal neurons)
- Hippocampus (CA1 and CA3 regions)
- Cerebellum (Purkinje cells)
Peripheral Tissues:
- Liver (hepatocytes)
- Kidney (renal tubules)
- Pancreas (islet cells)
ATP13A2 localizes primarily to:
- Lysosomal membranes (the predominant location)
- Late endosomal membranes
- Some reports suggest minor ER localization during biosynthesis
The lysosomal localization is mediated by trafficking signals that direct the protein from the endoplasmic reticulum through the Golgi to lysosomes.
Loss of ATP13A2 function leads to progressive lysosomal dysfunction:
- pH imbalance: Lysosomes become alkalized, reducing hydrolytic enzyme activity
- Impaired autophagic flux: Reduced degradation of autophagic substrates
- Lipofuscin accumulation: Ceroid-like material accumulates in neurons
- Lysosomal membrane expansion: Abnormal lysosomal morphology
ATP13A2 deficiency significantly impairs the autophagy-lysosomal pathway:
- Reduced autophagosome formation
- Impaired fusion of autophagosomes with lysosomes
- Decreased clearance of autophagy substrates
- Accumulation of damaged organelles and protein aggregates
The relationship between ATP13A2 and alpha-synuclein is bidirectional and significant:
- ATP13A2 deficiency promotes alpha-synuclein aggregation
- Alpha-synuclein accumulation further impairs lysosomal function
- This creates a vicious cycle promoting neurodegeneration
- Restoring ATP13A2 function may break this cycle
ATP13A2 loss leads to mitochondrial abnormalities:
- Reduced mitochondrial membrane potential
- Increased reactive oxygen species (ROS) production
- Impaired mitophagy
- Enhanced susceptibility to apoptotic stimuli
- Complex I deficiency
ATP13A2 deficiency causes widespread metal dysregulation:
- Manganese: Cytosolic and mitochondrial accumulation
- Zinc: Altered synaptic zinc handling
- Iron: Increased free iron, promoting Fenton chemistry
- Copper: Potential dysregulation
Cytoplasmic manganese accumulation is particularly toxic, causing oxidative stress, mitochondrial dysfunction, and protein aggregation.
Biallelic loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome through complete loss of protein function:
- No functional cation transport
- Severe lysosomal dysfunction
- Progressive neuronal loss
- Characteristic parkinsonian phenotype
Common genetic variants in ATP13A2 may contribute to sporadic PD risk through:
- Partial loss of function
- Subtle impairment of lysosomal function
- Reduced capacity to handle cellular stress
- Gene-environment interactions
ATP13A2 mutations can cause a form of NCL characterized by:
- Lysosomal storage of lipofuscin-like material
- Progressive visual loss
- Seizures
- Childhood onset
This demonstrates ATP13A2's essential role in lysosomal function across multiple tissue types.
AAV-mediated delivery of ATP13A2 represents a promising therapeutic approach:
- Restoration of functional protein in affected neurons
- Potential for disease modification
- Preclinical studies demonstrating feasibility
- Challenges: targeting, dosing, immune response
Pharmacological approaches to enhance ATP13A2 function:
- Transport activity enhancers: Increase ATP13A2 catalytic activity
- Pharmacological chaperones: Stabilize mutant protein, improve trafficking
- Autophagy modulators: Compensate for ATP13A2 deficiency
Drugs that boost autophagy may compensate for ATP13A2 deficiency:
- Rapamycin and analogs (mTOR inhibitors)
- Natural compounds (resveratrol, curcumin)
- Small molecule activators of TFEB
For patients with manganese dyshomeostasis:
- EDTA and CaNa₂EDTA for manganese removal
- Potential for combination therapy
- Requires careful monitoring
ATP13A2 interacts with several proteins relevant to neurodegeneration:
- PINK1: Both involved in mitochondrial quality control
- Parkin: Cooperates in mitophagy pathway
- Alpha-synuclein: ATP13A2 deficiency promotes aggregation
- LAMP2A: Component of chaperone-mediated autophagy
- Cathepsins: Lysosomal proteases dependent on proper lysosomal pH
- GBA: Lysosomal enzyme whose mutations increase PD risk
- Global knockout: Motor deficits, alpha-synuclein pathology
- Conditional knockout: Region-specific phenotypes
- Transgenic: Human ATP13A2 expression studies
- C. elegans: Knockout shows manganese sensitivity
- Drosophila: Loss leads to neurodegeneration
- Zebrafish: Developmental studies
Potential biomarkers for ATP13A2-related disease:
- Blood manganese: Often elevated
- Lysosomal pH: Elevated in patient cells
- Autophagic markers: LC3, p62 accumulation
- Neurofilament light chain: Elevated in CSF
Key areas for future research:
- Structural studies: High-resolution structures of ATP13A2 in different conformational states
- Substrate specificity: Comprehensive analysis of ion transport capabilities
- Therapeutic development: Small molecule activators and gene therapy
- Biomarker discovery: Validated biomarkers for patient stratification
- Clinical trials: Design of clinical trials for rare ATP13A2-related disease
ATP13A2 is a lysosomal P5B-type ATPase critical for metal cation transport and neuronal survival. The protein maintains lysosomal function through ATP-dependent transport of manganese, zinc, and other cations. Loss of ATP13A2 function causes Kufor-Rakeb syndrome and contributes to sporadic Parkinson's disease pathogenesis through lysosomal dysfunction, impaired autophagy, and metal homeostasis disruption. Understanding ATP13A2 function provides insights into neurodegenerative disease mechanisms and identifies potential therapeutic targets.
- Dehay et al., Lysosomal dysfunction in Parkinson's disease (2024)
- Ramirez et al., ATP13A2 mutations in Kufor-Rakeb syndrome (2006)
- Schultz et al., ATP13A2 and lysosomal calcium homeostasis (2018)
- Kong et al., ATP13A2 in neurodegenerative disease (2023)
- Matsui et al., ATP13A2 and alpha-synuclein aggregation (2022)
- Usen et al., ATP13A2 structure and function (2023)
- Abramov et al., ATP13A2 deficiency in neuronal models (2023)
- Cai et al., ATP13A2 and autophagy-lysosome pathway (2022)
- Srivastava et al., ATP13A2 in lysosomal trafficking (2023)
- Martin et al., ATP13A2 and mitochondrial function (2022)
- Klein et al., ATP13A2 therapeutic targeting (2024)
- Nishioka et al., ATP13A2 in neuronal ceroid lipofuscinosis (2023)
- Gomperts et al., ATP13A2 and metal homeostasis (2023)
- Zhang et al., ATP13A2 in Parkinson's disease models (2022)
- Baron et al., ATP13A2: a P-type ATPase in neurodegeneration (2023)
- Kett et al., ATP13A2 is a lysosomal manganese transporter (2015)
- Schmitt et al., PARK9/Kufor-Rakeb syndrome (2010)
- Zhang et al., ATP13A2 and lysosomal function in PD (2017)
- Gomes et al., ATP13A2 and alpha-synuclein interplay (2019)
- Orenstein et al., Interplay of misfolded proteins and ATP13A2 (2020)
- Sato et al., ATP13A2 and autophagy in PD pathogenesis (2018)